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Abstract
 
Lymphocyte membrane rafts contain molecules critical for immunoreceptor signaling. Here, we
report identification of a new raft-associated adaptor protein LIME (Lck-interacting molecule)
expressed predominantly in T lymphocytes. LIME becomes tyrosine phosphorylated after cross-
linking of the CD4 or CD8 coreceptors. Phospho-LIME associates with the Src family kinase Lck
and its negative regulator, Csk. Ectopic expression of LIME in Jurkat T cells results in an increase
 
of Csk in lipid rafts, increased phosphorylation of Lck and higher Ca
 
2
 
 
 
 response to CD3 stim-
ulation. Thus, LIME appears to be involved in regulation of T cell activation by coreceptors.
Key words: membrane microdomains • Lck • Csk • signal transduction • phosphorylation
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Introduction
 
Membrane microdomains, also called lipid rafts or glycolipid-
enriched microdomains, are small areas of cell membranes
that can be distinguished from the rest of the membrane by
unique lipid and protein composition. They are enriched
in lipids containing long saturated fatty acid residues
(mainly sphingomyelin and glycosphingolipids) and choles-
terol, glycosylphosphatidylinositol-anchored proteins, and
several cytoplasmic proteins associated with the inner leaflet
of the membrane via covalently attached fatty acid residues.
Among these cytoplasmic proteins are, e.g., Src family kinases
(possessing NH
 
2
 
-terminal double acylation) and heterotri-
meric G proteins. The integrity of membrane rafts seems to
be maintained by lateral interactions of their constituent
lipids which form, together with cholesterol, a more orga-
nized “liquid ordered” phase in the membrane. Membrane
rafts can be easily isolated due to their relative insolubility
in solutions of common mild detergents of the polyoxyeth-
ylene type (such as Triton X-100, Brij series, NP-40) at
low temperature and their ability to float when such detergent
lysates are ultracentrifuged in sucrose density gradient.
Conversely, membrane rafts are readily solubilized by
alkyl-glycosidic type of detergents (for general review on
 
the rafts and their role in immunoreceptor signaling see
references 1–3). Most transmembrane proteins are excluded
from lipid rafts, exceptions being few molecules palmitoy-
lated on cytoplasmic membrane-proximal cysteine residues,
such as the pre-TCR (4), the CD4 and CD8 coreceptors
(5, 6), and the three recently discovered transmembrane
adaptor proteins, linker for activation of T cells (LAT) (7, 8),
phosphoprotein associated with glycosphingolipid-enriched
microdomains (PAG) (9), or Csk-binding protein (Cbp)
(10) and non–T cell activation linker (NTAL) (11) or
linker for activation of B cells (LAB) (12).
Because of the presence of several key signal-transducing
molecules (Src family kinases, transmembrane adaptor proteins
LAT, NTAL/LAB, and PAG/Cbp), membrane rafts have
been shown recently to play an essential role in initiation of
immunoreceptor (TCR, BCR, FcR) signaling (1–3). To
identify novel lipid raft-associated transmembrane adaptor
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Abbreviations used in this paper:
 
 Cbp, Csk-binding protein; LAT, linker for
 
activation of T cells; LAB, linker for activation of B cells; LIME, Lck-
interacting molecule;
 
 
 
NTAL, non–T cell activation linker; PAG, phos-
phoprotein associated with glycosphingolipid-enriched microdomains;
 
PBL, peripheral blood leukocytes; PHA, phytohemagglutinin; PLC
 
 
 
,
 
phospholipase C
 
 
 
; PTK, protein tyrosine kinase; P-Tyr, phosphotyrosine;
SH Src homology; TRAP, transmembrane adaptor protein; TRIM,
TCR-interacting molecule.T
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proteins, we have searched public databases for molecules
sharing the structural features characteristic of raft-targeted
transmembrane adaptor proteins. One of the proteins
identified by this approach was Lck-interacting molecule
(LIME), a molecule of unknown function whose amino
acid sequence has been deposited in the databases since
1998. In the present study we describe the first biochemical
and functional characterization of LIME.
 
Materials and Methods
 
Cells and Antibodies.
 
T, B, and NK cells and monocytes were
obtained from buffy coats by Ficoll centrifugation and preparative
cell sorting using a FACS Vantage
 
TM
 
 flow cytometer (Becton
Dickinson) and PE-conjugated mAbs to CD3 and CD19 (Sero-
tec), biotinylated anti-CD14 (Serotec), fluoresceinylated (FITC)
streptavidin (BD Biosciences), unlabeled CD56 mAb MEM-188,
and fluorescein-conjugated F(ab)
 
2
 
 fragments of goat anti–mouse
Ig (Caltag). Single-positive (CD4
 
 
 
8
 
 
 
, CD4
 
 
 
8
 
 
 
), double-positive
(CD4
 
 
 
8
 
 
 
), and double-negative (CD2
 
 
 
CD4
 
 
 
CD8
 
 
 
CD19
 
 
 
)
thymocytes were isolated by flow sorting using anti–CD4-FITC
(MEM-241), anti–CD8-PE (BD Biosciences), anti–CD2-PE
(Immunotech), anti–CD4-biotin (Serotec), anti–CD8-biotin (Se-
rotec), anti–CD19-biotin (Serotec), and Streptavidin-FITC (BD
Biosciences) mAbs. Purity of all sorted thymocyte subpopulations
used in subsequent experiments was 
 
 
 
99%. In some experiments,
the peripheral blood leukocytes (PBLs) obtained by Ficoll centrif-
ugation were passed through nylon wool column, the nonadher-
ing T and NK cells were recovered and are referred to as periph-
eral blood T cells. 293T cells were from the cell line collection of
the Institute of Molecular Genetics. T cell line J77 (CD4
 
 
 
 Jurkat)
was provided by Dr. O. Acuto (Institut Pasteur, Paris, France).
Antiserum to LIME was produced in the Prague laboratory by
immunization of rabbits with bacterially expressed and Talon
purified (CLONTECH Laboratories, Inc.) cytoplasmic fragment
of human LIME (described under constructs), and mouse mAbs
to LIME were prepared using standard techniques from spleno-
cytes of mice immunized with the same bacterially produced
LIME fragment. In addition, antipeptide mAbs were prepared
against the COOH-terminal peptide comprising residues 281–
296 of the human molecule (purchased from PolyPeptide Labo-
ratories) conjugated to keyhole limpet hemocyanin using a com-
mercial kit (Pierce Chemical Co.). Rabbit antiserum to LAT
(13) was provided by Dr. L. Samelson (National Institute of
Child Health and Human Development, National Institutes of
Health, Bethesda, MD).
The sources of the other antibodies used were as follows: mAb
to phosphotyrosine (4G10; UBI), rabbit polyclonal antibodies to
Erk1/2 (Promega), phospho-Lck (Tyr
 
505
 
) and phospho-Src fam-
ily (Tyr
 
416
 
) (New England Biolabs, Inc.), Csk (Santa Cruz Bio-
technology, Inc.), mAbs to CD3 (OKT3; Ortho), CD28 (IgM
isotype; provided by Dr. U. Moebius, University of Heidelberg,
Germany), and CD4 (B66.1; donated by Dr. C.T. Baldari, Uni-
versity of Siena, Siena, Italy). mAbs to Lck (LCK-01), CD4
(MEM-16, MEM-115, MEM-241), CD8 (MEM-31), CD3
 
 
 
(MEM-92, MEM-57), CD20 (MEM-97), and CD56 (MEM-
188) were all prepared in the Prague laboratory.
 
Immunoprecipitation, In Vitro Kinase Assay, and Other Biochemical
Methods.
 
LIME and LIME-containing complexes were immu-
noprecipitated from postnuclear supernatants of cells solubilized
by a detergent effectively disrupting lipid rafts (laurylmaltoside
[
 
N
 
-dodecyl 
 
 
 
-D-maltoside]; Calbiochem) (lysis buffer: 1% lau-
 
rylmaltoside in 20 mM Tris, pH 7.5, containing 100 mM NaCl,
10% glycerol, 1 mM 4-[2-aminoethyl]-benzenesulfonyl fluoride,
10 mM EDTA, 50 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
) using CNBr-
Sepharose beads (Amersham Biosciences) coupled with mAbs pu-
rified by protein A–Sepharose affinity chromatography. The
lysates were passed through minicolumns (30–50 
 
 
 
l packed vol-
ume) of such immunosorbents; after washing with 10 column
volumes of lysis buffer, bound proteins were eluted with 2 col-
umn volumes of 2
 
 
 
 concentrated SDS sample buffer and the
flow-through, and eluted fractions were analyzed by SDS-PAGE
followed by Western blotting.
In vitro kinase assays were performed as described before (14).
Briefly, cells were solubilized in ice cold 1% laurylmaltoside lysis
buffer (see previous paragraph), and the postnuclear supernatants
were incubated in plastic wells coated with appropriate mAbs.
After washing, the kinase solution (20 mM Hepes, pH 7.4, 5 mM
MgCl
 
2
 
, 5 mM MnCl
 
2
 
, 0.1% detergent Igepal [Sigma-Aldrich])
containing 0.1 
 
 
 
Ci [
 
 
 
-
 
32
 
P]ATP (ICN) per well was added, and
the proteins phosphorylated by kinases present in the immuno-
precipitates were resolved by SDS-PAGE followed by autora-
diography and immunoblotting. In some cases, purified cytoplas-
mic domain of TCR-interacting molecule
 
 (
 
TRIM) protein (15)
(30 
 
 
 
g/ml) was used as an exogenous Lck substrate and added to-
gether with 0.5 
 
 
 
Ci [
 
 
 
-
 
32
 
P]ATP per well. At the end of the test,
the content of the wells was taken and processed for SDS-PAGE
and autoradiography. For control, the wells were then washed,
and phosphorylated proteins in immunoprecipitates were re-
solved as in the standard kinase assay. Lipid raft separation by su-
crose gradient ultracentrifugation was performed essentially as
described before, using 3% Brij-58 detergent for membrane solu-
bilization; the density gradient fractions were analyzed by SDS
PAGE and Western blotting (9). In some experiments, cells were
directly solubilized in 2
 
 
 
 concentrated SDS sample buffer, ultra-
centrifuged (250,000 
 
g
 
, 30 min), and the supernatant was ana-
lyzed by SDS-PAGE and Western blotting. Biosynthetic labeling
with 
 
3
 
H-palmitate, SDS-PAGE, and Western blotting were per-
formed as described (11).
 
PCR.
 
Nested PCR with two sets of primers (first 5
 
 
 
-
GAGAATTCTGCACAAAGACCTTCCTGG-3
 
 
 
 plus 5
 
 
 
-GAG-
AATTCACAGGTCCTTGAGTGTTCAG-3
 
 
 
 and then the same
5
 
 
 
 end primer plus 5
 
 
 
-GCAGCACCCTAGAACCCAGA-3
 
 
 
primer) was used to detect the LIME cDNA in the Multiple Tis-
sue Panels I and II and the Immune System Panel (CLONTECH
Laboratories, Inc.).
 
DNA Constructs and Transfections.
 
The coding region of hu-
man LIME was amplified from human leukocyte cDNA library
(CLONTECH Laboratories, Inc.) (primers: 5
 
 
 
-GAGAATTCT-
GCACAAAGACCTTCCTGG-3
 
 
 
 and 5
 
 
 
-GAGAATTCACAG-
GTCCTTGAGTGTTCAG-3
 
 
 
). The PCR product was cloned
into EcoRI site of pBluescript SK vector (Stratagene) and se-
quenced. For bacterial expression, the LIME intracellular frag-
ment corresponding to aa 141–295 was cloned into XhoI and
BamHI sites of pET-15b expression vector (Novagen), generat-
ing a construct with NH
 
2
 
-terminal histidine tag. For expression
in eukaryotic cells, LIME coding sequence was subcloned into
EcoRI site of pEFIRES-N vector (16) (provided by Dr. S.
Hobbs, Institute of Cancer Research, London, UK). For transient
transfection of 293T cells, Lipofectamine 2000™ reagent (Invi-
trogen) was used according to manufacturer’s instructions. For
transfection experiments in 293T cells, the following cDNA con-
structs were used: Flag-tagged Lck and Myc-tagged ZAP-70 in-
serted into pcDNA3 vector (donated by Dr. R. Abraham, Mayo
Clinic, Rochester, Minnesota), Fyn cloned in pSR
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vector (provided by Dr. A. da Silva, Dana Farber Cancer Insti-
tute, Boston, MA), Csk in pEF-BOS vector (9), Syk cloned into
the pRK5 vector (provided by Dr. W. Kolanus, Gene Center,
Munich, Germany), Myc-tagged Lyn in pcDNA3.1 vector (pro-
vided by Dr. S. Watson, University of Oxford, Oxford, UK), and
Flag-tagged Hck in pcDNA1 vector (provided by Dr. G. Langs-
ley, Institut Pasteur, Paris, France).
J77 cells (Jurkat T cell line expressing CD4; essentially devoid
of endogenous LIME expression) were transfected with the
LIME-pEFIRES-N construct by electroporation, and stable
transfectants were selected by growing the cells in 96-well plate
in selective medium containing 1 mg/ml G418 (Calbiochem).
After 3 wk, oligoclonal G418-resistant populations were ex-
panded and checked for LIME expression by Western blotting.
Single Tyr
 
→
 
Phe mutants were produced by site-directed mu-
tagenesis using the QuickChange XL Site-Directed Mutagenesis
kit (Stratagene) according to the manufacturer’s protocol.
COOH-terminally FLAG-tagged NTAL was produced by site-
directed mutagenesis using the same kit; FLAG-tagged LIME
construct was generated by PCR using the primer containing se-
quence for FLAG. All mutated nucleotide sequences were veri-
fied by full-length sequencing and subcloned to pEFIRES-N.
For overexpression in peripheral blood T cells, LIME was sub-
cloned into EcoRI site of pXJ41 vector (17), and the transfection
was performed using the nucleofector apparatus and human T cell
nucleofector kit (Amaxa Biosystems) according to the manufac-
turer’s instructions.
 
Confocal Microscopy.
 
J77-LIME transfectants were spun on
coverslips coated with poly-
 
l
 
-lysine (Sigma-Aldrich), and fixed
and permeabilized 3 min in 
 
 
 
20
 
 
 
C methanol and then 5 s in cold
acetone. After washing in PBS, the slides were blocked in PBS
containing 1% BSA and incubated 45 min with mouse mAb to
LIME (LIME-1, 50 
 
 
 
g/ml), followed by 45 min incubation with
Alexa 488 goat anti–mouse IgG (Molecular Probes, 500
 
 
 
 di-
luted). Nuclei were stained with propidium iodide (Molecular
Probes, 10 min, 0.5 
 
 
 
g/ml). The samples were mounted in PBS
and viewed on a Laserscan microscope (Leica TCS SP). Incuba-
tion with irrelevant primary antibody and staining of nontrans-
fected J77 cells served as a negative control.
 
Cell Activation.
 
Peripheral blood T cells were stimulated by 2
min incubation with anti-CD3 (MEM-92) or anti-CD4 (MEM-
16) IgM mAbs (
 
 
 
10 
 
 
 
g/ml) at 37
 
 
 
C. In some experiments, a
combination of anti-CD4 mAbs (MEM-16 
 
 
 
 MEM-115
[IgG] 
 
 
 
 MEM-241 [IgG]; 
 
 
 
10 
 
 
 
g/ml each) for 2 min at 37
 
 
 
C
was used. When IgG mAbs alone were used (anti-CD4 [MEM-
241], anti CD8 [MEM-31]), the cells were first preincubated 30
min on ice with the primary antibody (
 
 
 
10 
 
 
 
g/ml), washed with
ice cold medium, and stimulated by cross-linking with 10 
 
 
 
g/ml
goat anti–mouse polyclonal antibody (ICN) for 2 min at 37
 
 
 
C.
The cells were then lysed, subjected to LIME immunoprecipita-
tion, and LIME phosphorylation was determined by anti-phos-
photyrosine (P-Tyr) immunoblotting. In some experiments the
cells were pretreated for 7–20 min with 2.5–10 
 
 
 
g/ml of the Src
kinase family inhibitor PP2 (Calbiochem).
For long term activation, culture dishes were precoated with
purified sterile anti-CD3 mAb MEM-57 (IgG2a; final concentra-
tion 10 
 
 
 
g per ml of 0.1 M Tris, pH 9.5) for 4 h at 37
 
 
 
C. Dishes
were washed three times with RPMI medium without serum,
and 5 million T cells, resuspended in 5 ml RPMI supplemented
with FCS and 500 IU IL-2 (Chiron), were seeded per 5-cm dish.
Cells were then cultured, harvested, and lysed at indicated time
points. Where indicated, cells were removed from the anti–CD3-
coated dish, washed, and cultured in a new uncoated dish in the
 
presence of IL-2 (100 IU/ml). For phytohemagglutinin (PHA)
stimulation, PBLs were cultured for 3 d in RPMI medium with
10% FCS and PHA (Wellcome Reagents; commercial stock solu-
tion diluted for optimal activity 50
 
 
 
).
To measure Ca
 
2
 
 
 
 response to anti-CD3 activation, J77 cells
were electroporated either with FLAG-tagged LIME or NTAL
expression constructs or with an empty pEFIRES-N vector. After
48 to 72 h in culture, the cells were transferred to Hepes-buffered
Hank’s balanced salt solution with 1% FCS and loaded with Fluo-
4 and Fura Red dyes (Molecular Probes, each 1 
 
 
 
g/100 
 
 
 
l con-
taining 10
 
6
 
 cells) for 20 min at room temperature. The cells were
washed in the same buffer incubated for 10 min at room tempera-
ture and then warmed for 10 min at 37
 
 
 
C. The measurement was
performed on the FACSort™ flow cytometer (Becton Dickinson)
in a heated holder (37
 
 
 
C); after measuring the baseline, the anti-
CD3 IgM mAb MEM-92 (10
 
5
 
 diluted ascitic fluid) was added,
and eventually, when the response subsided the calcium iono-
phore ionomycin (Molecular Probes) was used to determine the
absolute maximal response. The analysis was performed using the
FlowJo program (Tree Star, Inc.). From a kinetic curve con-
structed from ratios of Fluo-4 to FuraRed fluorescence, the aver-
age baseline, the maximum after anti-CD3 stimulation, and the
average response to ionomycin were deduced.
 
Results
LIME, A Novel Lipid Raft-Associated Transmembrane
Adaptor Protein. Public databases were searched for pro-
teins possessing the following structural features: (a) an
NH2-terminal peptide consisting of 5–50 amino acids fol-
lowed by a transmembrane helix; (b) a palmitoylation motif
(CxxC) starting 0–4 amino acids downstream from the
transmembrane helix; and (c) at least one tyrosine-based
motif (Yxx[I/L/V]) in the COOH-terminal (presumably
cytoplasmic) portion of the protein. This approach yielded
a number of candidate proteins, most of them being false
positives (e.g., proteins with NH2-terminal signal pep-
tide). However, the search identified also the already
known transmembrane adaptors PAG/Cbp and NTAL/LAB.
Among several other potentially interesting molecules we
identified a protein carrying the GenBank/EMBL/DDBJ
accession no. BAA91148. BLAST search revealed that the
sequence of its murine homologue, LIME (standing for
“Lck interacting molecule”) is also available under Gen-
Bank/EMBL/DDBJ accession no. AAG35210. Although
Hur et al. (18) submitted the sequence to the database al-
ready in 1998, no biochemical or functional characteriza-
tion of LIME has been reported up to now.
The human LIME cDNA codes for a strongly basic
polypeptide (predicted pI 9.7) of 295 amino acid residues
and a predicted molecular weight of 31,229 daltons (Fig. 1).
The leaderless type III protein consists of a very short NH2-
terminal extracellular peptide (4 aa), a single putative hydro-
phobic transmembrane domain (23 aa), which is followed
by a potential palmitoylation site (a CxxC motif) and two
arginine residues. The predicted cytoplasmic domain con-
tains a total of five tyrosines, all potentially phosphorylated
by Src family kinases. Two of the tyrosine-based signaling
motifs (Y200 and Y235, respectively) potentially represent im-
munoreceptor tyrosine-based inhibition motifs.T
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LIME transcripts were detected by PCR in cDNA pre-
pared from PBLs, various lymphoid tissues, and liver but
not other tissues (Fig. 2, A and B). In Western blotting ex-
periments, both polyclonal and monoclonal antibodies di-
rected to COOH-terminal fragments of LIME recognized
a zone of the appropriate size in peripheral blood T cells,
which strongly increased in intensity after overexpression
of LIME (Fig. 2 C). Strong expression of LIME was also
observed in purified CD56  cells (mixture of NK cells and
NK T cells). However, when further separated NK cells
(CD3-negative) were found to express only little LIME
compared with NK T cells (unpublished data). Similarly,
purified blood B lymphocytes express only low amounts of
LIME, and the molecule seems to be absent in monocytes
(Fig. 2 D). In addition, all thymocyte subsets (double nega-
tive, double positive, single positive) contained comparable
amounts of LIME, and no marked differences in the level
of LIME expression could be detected in purified subsets of
peripheral blood T cells (CD4 , CD8 , CD45RA ,
CD45RO , CD4 CD25 , CD4 CD25 ,    Tcells; not
depicted). Among the T cell lines tested (Jurkat, HPB ALL,
HUT-78, SupT1, Molt-4, and CEM), only Jurkat cells are
essentially negative for LIME protein expression (not de-
picted). Expression of LIME strongly decreased when pe-
ripheral blood T cells were activated in vitro for several
days using PHA or plastic-immobilized CD3 mAb (Fig. 2,
E and F). When the stimulated T cells were transferred in
new culture dishes and cultivated further in the absence of
external stimuli, LIME became rapidly and strongly reex-
pressed (Fig. 2 F). These data suggest that expression of
LIME in peripheral blood T cells is controlled by external
stimuli mediated via the TCR (or other PHA-responsive
cell surface receptors).
As shown in Fig. 3, LIME is mostly present in buoyant
lipid rafts (Fig. 3 A) and can be biosynthetically labeled by
3H-palmitate (Fig. 3 B), indicating that the membrane-
proximal putative palmitoylation motif is used for targeting
the protein into lipid rafts. Moreover, LIME clearly local-
izes to the plasma membrane as judged from confocal mi-
croscopy of Jurkat T cells stably overexpressing the mole-
cule (Fig. 3C). Collectively, these data suggest that LIME
represents an integral membrane protein associated with
lipid rafts.
Figure 1. Predicted amino acid sequence of human LIME. The putative
transmembrane region is boxed, and the potential palmitoylation sequence
and tyrosine motifs are in bold and underlined.
Figure 2. Expression of LIME. (A) Presence of LIME mRNA in various
tissues as detected by PCR from the Multiple Tissue cDNA Panels I and
II (CLONTECH Laboratories, Inc.) and (B) the Immune System Panel
(CLONTECH Laboratories, Inc.). (C) Western blotting of vector- and
LIME-transfected peripheral blood T cells (immunostaining for LIME
and LAT; the latter was used as a loading control). (D) Western blotting of
indicated subpopulations of human peripheral blood cells (immunostaining
for LIME and Erk1/2; the latter was used as a loading control). (E) Western
blotting of resting and PHA-activated peripheral blood T cells (immunostain-
ing for LIME and LAT; the latter was used as a control). (F) Kinetics of
LIME downmodulation in peripheral blood T cells stimulated by immo-
bilized anti-CD3 mAb and LIME reexpression after removal of the cells
from anti-CD3–coated wells (after day 3) and further culturing in the
presence of IL-2. Cell lysates were analyzed by Western blotting for the
presence of LIME and LAT. The same results were obtained when IL-2
was not added to the culture medium (not depicted).
Figure 3. Subcellular localization of LIME. (A) Localization of LIME
in buoyant detergent-resistant microdomains (lipid rafts). Peripheral
blood T cells were solubilized in the presence of 3% nonionic detergent
Brij-58 and subjected to sucrose density gradient ultracentrifugation; the
fractions (numbered from top to bottom) were analyzed by Western blotting.
(B) Biosynthetic labeling of LIME with 3H-palmitate; LIME immunopre-
cipitate was analyzed by SDS-PAGE followed by fluorography of the gel
(the 56-kD zone corresponds probably to associated Lck). (C)  Plasma
membrane localization of LIME (green) as determined by confocal mi-
croscopy in J77-LIME.T
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Engagement of the CD4 or CD8 Coreceptors Induces Tyrosine
Phosphorylation of LIME and Its Association with Protein Tyro-
sine Kinases Lck and Csk. The overall similarity between
LIME, LAT, PAG/Cbp, and NTAL/LAB indicated that
LIME might be inducibly tyrosine phosphorylated after li-
gation of some cell surface receptor(s). To identify such re-
ceptors, a broad screening involving antibody-mediated
cross-linking of multiple lymphocyte surface molecules was
performed. This approach revealed that LIME becomes ty-
rosine-phosphorylated exclusively after antibody-mediated
engagement of the CD4 or CD8 coreceptors (Fig. 4)
but not after triggering CD2, CD3, CD5, CD7, LFA-1,
CD43, CD45, or MHC class I (not depicted). Cocross-
linking of CD4 and CD3 consistently produced lower lev-
els of LIME tyrosine phosphorylation than CD4 cross-link-
ing alone (not depicted).
As shown in Fig. 4 C, after cross-linking of CD4 phos-
phorylation of LIME was maximal after 2 min and slowly
declined thereafter. LIME became also tyrosine phosphory-
lated after cross-linking of CD4 on the surface of anti-CD3
activated, IL-2–propagated T cell blasts (not depicted).
To determine which protein tyrosine kinases (PTKs)
might be responsible for phosphorylation of LIME, we
treated human peripheral blood T cells with the Src family
PTK inhibitor PP2 before CD4 cross-linking. As shown in
Fig. 4 D, pretreatment with PP2 strongly suppressed the
CD4-mediated tyrosine phosphorylation of LIME. In
agreement with this result, coexpression of LIME with the
protein tyrosine kinases Fyn, Lck, Lyn, Hck, Csk, Syk, or
ZAP-70 in 293T-cells revealed that LIME represents a sub-
strate for PTKs of the Src family, in particular Lck or Lyn
(Fig. 4 E).
The next series of experiments was performed to assess
molecular interactions between LIME and other signaling
molecules expressed in T cells. These experiments indi-
cated that the Src family kinase Lck and the negative regu-
lator of Src kinases, the Csk kinase, specifically associate
with phosphorylated LIME in CD4-stimulated T lympho-
cytes (Fig. 5 A). Analysis of the LIME immunoprecipitates
using phosphospecific antibodies further suggested that
LIME-associated Lck was phosphorylated on both the
COOH-terminal inhibitory and the activating tyrosine res-
idues (Y505 and Y394, respectively; Fig. 5 A). The inducible
association of LIME with PTK activity was also demon-
strated by an in vitro kinase assay using LIME immunopre-
cipitates prepared from unstimulated or anti-CD4–stimu-
lated T cells (Fig. 5 B).
Strikingly, when stably expressed in the CD4-positive
Jurkat T cell line (J77), LIME displayed constitutive strong
tyrosine phosphorylation and bound Lck, Csk, and also
Fyn (Fig. 6) even without CD4 cross-linking; constitutive
tyrosine phosphorylation of LIME was observed also in all
Figure 4. Induction of LIME
tyrosine phosphorylation. (A) Pe-
ripheral  blood T cells were left
unstimulated ( ) or stimulated
via CD3 or CD4, and LIME was
immunoprecipitated from lauryl-
maltoside lysates and analyzed by
Western blotting to visualize
tyrosine-phosphorylated LIME
(top) and total LIME (bottom).
(B) As in A but using purified
CD8  T cells stimulated by
mAbs to CD4 (negative control),
CD8, or not stimulated ( ). (C)
Kinetics of LIME phosphoryla-
tion after T cell stimulation via
CD4; stimulation was stopped
after the indicated times (0–30
min). Immunoprecipitated LIME
was analyzed by Western blotting
using antibodies to P-Tyr (top)
or LIME (bottom). (D) Inhibition of anti–CD4-induced LIME phosphorylation in T cells by the inhibitor of Src kinases PP2. LIME immunoprecipitates
were analyzed by Western blotting for P-Tyr and LIME. (E) Kinases phosphorylating LIME were examined by cotransfection of constructs encoding
LIME, and the indicated kinases in 293T cells; total cell lysates were analyzed by Western blotting using antibodies to P-Tyr (top) or LIME (bottom).
Expression of all the kinases was verified separately (not depicted).
Figure 5. Proteins associated with phosphorylated LIME. (A) LIME
immunoprecipitates prepared from unstimulated (left) or anti–CD4-
stimulated (right) T cells (solubilized under raft-dissociating conditions)
were analyzed by Western blotting using antibodies to the indicated
molecules. (B) In vitro kinase assay of the LIME immunoprecipitates
obtained from unstimulated and anti–CD4-stimulated T cells; as a neg-
ative control (Ctr.) an irrelevant antibody (anti-CD20) was used for the
immunoprecipitation.T
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T cell lines expressing LIME naturally [unpublished data]).
Moreover, the level of LIME phosphorylation and its asso-
ciation with Lck and Csk, respectively, did not change sig-
nificantly in these transfectants after CD4 cross-linking.
However, brief pretreatment of these transfectants with the
Src family PTK inhibitor PP2 led to a substantial decrease
of the constitutive phosphorylation of LIME; in such pre-
treated cells, LIME rephosphorylation could be achieved
by cross-linking of CD4 by antibodies or recombinant
HIV-derived gp120 (not depicted). The reason for the
constitutive tyrosine phosphorylation of LIME in J77 is un-
clear at present but might be due to a deregulation of the
membrane-proximal signaling pathways in the transformed
cells (see Discussion).
To assess which tyrosine residues of LIME mediate its
interaction with Lck and Csk, respectively, a series of stable
J77 transfectants were generated expressing tyrosine mu-
tants of LIME. It could be demonstrated that Y254 repre-
sents the binding site for Lck (and Fyn) (Fig. 6). Indeed,
this site corresponds to a high stringency binding site for
Lck and Fyn as predicted by the scansite program (http://
scansite.mit.edu) (19). In contrast, phosphorylated Y167 and
potentially also Y200 appear to mediate the interaction be-
tween LIME and Csk. These tyrosine-based signaling mo-
tifs readily fit the consensus sequence that is found in vari-
ous Cbps and the consensus sequence selected from peptide
libraries (Table I).
Further analysis of the J77-LIME transfectant indicated
that the amounts of lipid rafts-associated Lck and Csk are ei-
ther slightly (in the case of Lck) or strongly increased (in the
case of Csk) in these cells compared with WT J77 cells (Fig.
7 C). These data confirm that tyrosine-phosphorylated
LIME is capable of targeting Lck and Csk to lipid rafts.
The data shown in Fig. 7 A demonstrate that in J77-
LIME transfectants the LIME-associated fraction of Lck is
more strongly phosphorylated on the inhibitory tyrosine
Y505 compared with the total pool of Lck. In addition, an in
vitro kinase assay of Lck immunoprecipitates prepared from
J77-LIME cells results in a much stronger phosphorylation
of Lck than in WT J77 cells (Fig. 7 B). Furthermore, LIME-
associated Lck was even stronger phosphorylated than Lck
immunoprecipitated from the total pool of Lck in the J77-
LIME cells (Fig. 7 B). This could be either due to a higher
enzymatic activity of the LIME-associated Lck (resulting in a
higher level of autophosphorylation) or due to an increased
phosphorylation of Lck by LIME-associated Csk.
Figure 6. Identification of the P-Tyrs involved in binding of Lck, Fyn,
and Csk. LIME immunoprecipitates from lysates of J77 cells stably trans-
fected with the indicated Tyr to Phe mutants of LIME were analyzed by
Western blotting for the presence of the indicated molecules.
Table I. Comparison of Published Csk Binding Sequences
Protein name and binding site position Csk binding sequence Reference
LIME Y167 V A E Y A R V Q K R K This paper
LIME Y200 D V L Y S R V C K P K This paper
Paxillin Y118 E H V Y S F P N K Q K 39
Caveolin Y14 G H L Y T V P I R E Q 40
PTP-HSCF Y354 A D T Y A V V Q K R G 41
PTP-HSCF Y381 T P I Y S Q V A P R A 41
IGF-IR Y943 G V L Y A S V N P E Y 42
IGF-IR Y1316 R Q P Y A H M N G G R 42
InsulinR Y1322 H I P Y T H M N G G K 42
p62dok Y449 S A L Y S Q V Q K S G 43
PAG Y317 S A M Y S S V N K P G 9
SIT Y169 P E L Y A S V C A Q T 44
Hic-5 Y60 D H L Y S T V C K P R 45
Peptide library Y[T/A/S][K/R/Q/N][M/I/V/R] 46
Critical tyrosines are bolded, other amino acids participating in the putative consensus motif are underlined.T
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To distinguish between these possibilities, we assessed
the capability of Lck to phosphorylate an exogenous sub-
strate (the cytoplasmic domain of the transmembrane adap-
tor protein TRIM, which has been shown to be an excel-
lent substrate for Lck in vivo [20]). As shown in Fig. 7 B
(top), the ability of Lck to phosphorylate TRIM appears to
be the same in J77-LIME cells and in J77 cells transfected
with an empty vector. These data collectively support the
hypothesis that the higher levels of tyrosine phosphoryla-
tion of LIME-associated Lck primarily result from phos-
phorylation of Y505 by the LIME-associated Csk. More-
over, they suggest that expression of LIME in Jurkat T cells
leads to increased phosphorylation of Lck by Csk without
dramatically altering the enzymatic activity of Lck. This
finding can be best explained by the fact that the Src ho-
mology (SH)2 domain of Lck is not available for interac-
tion with phospho-Y505 because it is engaged by phosphor-
ylated LIME (Y254), and therefore, the closed inactive
conformation of Lck cannot be formed.
LIME Increases Ca2  Response After Stimulation of J77
Cells. Transient expression of LIME in J77 cell leads to a
significantly higher Ca2  response to anti-CD3 stimulation
compared with cells transfected with an empty vector,
whereas another raft-associated transmembrane adaptor
protein NTAL, expressed at the same level, does not
change this response significantly (Fig. 8).
Discussion
Transmembrane adaptor proteins (TRAPs) are emerging
as important molecules involved in coupling immunore-
ceptors to intracellular signaling pathways (1–3). Two types
of TRAPs can be distinguished, namely those that are ex-
cluded from the rafts (TRIM [20], SHP2-interacting trans-
membrane adaptor [21], and linker for activation of X
[LAX] [22]) and those that are targeted to rafts via jux-
tamembrane palmitoylation of a di-cysteine motif CxxC
(LAT [7, 8], PAG/Cbp [9, 10], NTAL/LAB [11, 12],
and LIME). The increasing number of the raft-associated
TRAPs is in agreement with the currently recognized im-
portance of membrane rafts in receptor signaling and other
cellular processes (1–3). LAT and NTAL/LAB are in-
volved in signaling initiated by immunoreceptors (TCR
and BCR or Fc receptors, respectively [11, 12, 23]),
whereas PAG/Cbp participates more generally in negative
regulation of Src family kinases and thus indirectly controls
immunoreceptor signaling (9, 10, 24–26).
LIME, the novel TRAP described herein, appears not to
be a direct target of immunoreceptor-mediated signaling
events. Rather, its phosphorylation and association with in-
tracellular signaling and effector molecules (Lck and Csk)
seems to be controlled in primary T cells by the corecep-
tors CD4 and CD8. Csk and Lck (plus Fyn) also associate
with LIME when the molecule is expressed in the J77 Jur-
kat T cell line; notably, in these transfectants LIME is con-
stitutively tyrosine phosphorylated, and its phosphorylation
status apparently does not change upon CD4 (nor CD3)
cross-linking. Importantly, the Lck molecules that associate
with phosphorylated LIME are phosphorylated both on the
COOH-terminal negative regulatory Y505 and on the posi-
tive regulatory Y394 and exhibit somewhat paradoxically an
increased autophosphorylation activity. It seems likely that
the inhibitory phospho-Y505 is unable to exert its inhibitory
Figure 7. Effects of LIME on Lck and Csk in J77-LIME stable trans-
fectants. (A) The concentration of directly immunoprecipitated Lck was
adjusted to equate on the Western blot to the amount of Lck coprecipi-
tated with LIME (top), and the blot was then stained with antibody spe-
cifically recognizing the phosphorylated Tyr505. (B) In vitro kinase assay
was performed using purified cytoplasmic domain of TRIM protein as an
exogenous substrate for Lck immunoprecipitated from J77-LIME trans-
fectants or from cells transfected with an empty vector. The phosphorylated
proteins in immunoprecipitates were also resolved to check content (immu-
noblotting) and phosphorylation status (autoradiography) of Lck. The
dividing lines in the TRIM panel indicate that these lanes were not adjacent
in the original gel, and the far right-hand lane is from a different gel, which
was processed simultaneously. (C) Localization of Lck and Csk in lipid
rafts of J77-LIME transfectants or cells transfected with an empty vector.
Cells were solubilized in the presence of 3% nonionic detergent Brij-58
and subjected to sucrose density gradient ultracentrifugation; the fractions
(numbered from top to bottom) were analyzed by Western blotting.
Figure 8. Effects of LIME on anti–CD3-induced Ca2  response. J77
cells transiently transfected with the indicated constructs were stimulated
by cross-linking of CD3. The results are presented as a proportion of the
peak anti-CD3 response to the maximum response induced by Ca2  ion-
ophore ionomycin after correction for basal level. The results are repre-
sentative of three independent experiments and show the mean and SD of
four measurements. The observed increase is statisticaly significant at the
5% level (Student’s t test). The right panel shows the comparable level of
LIME and NTAL expression as determined by Western blotting and
immunostaining of FLAG tag.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
Transmembrane Adaptor Protein LIME 1460
function, since the Lck SH2 domain is bound to the phos-
pho-LIME (see further discussion of this point below).
Interestingly, despite the presence of two putative im-
munoreceptor tyrosine-based inhibition motifs in the cyto-
plasmic tail of LIME, so far we could not detect any SH2
domain containing phosphatase (SHP-1, SHP-2, or SHIP)
in LIME immunoprecipitates prepared from activated
(even pervanadate-treated) cells.
What are possible biological functions of this novel raft-
associated adaptor? Induction of tyrosine phosphorylation
and association with Lck and Csk after CD4 or CD8 cross-
linking strongly indicates that LIME plays a role in regula-
tion or propagation of coreceptor signaling.
The roles of the coreceptors (so far studied mainly for
CD4) may be twofold, depending on whether the corecep-
tor is coengaged with the TCR or cross-linked separately.
Cocross-linking of CD4 with the TCR generally potenti-
ates TCR-mediated signaling events, obviously due to
bringing the CD4-associated fraction of Lck into the prox-
imity of the cytoplasmic tails of the CD3 complex and the
  chains (27, 28). LIME might play a potentiating role in
this physiological signaling. This view is supported by our
observation that transient overexpression of LIME in J77
Jurkat T cells increases Ca2  responses after CD3 stimula-
tion. Moreover, when stably expressed in J77 cells LIME is
expressed as a constitutively phosphorylated protein. This
could correspond to the situation that occurs in primary T
cells after coreceptor engagement.
In contrast to coengagement with the TCR, separate
cross-linking of CD4 either by antibodies to suitable CD4
epitopes or by HIV gp120 is known to inhibit or markedly
modify the outcome of the subsequent signaling induced
by TCR engagement (29, 30). Moreover, in rodent mod-
els selective ligation of CD4 in vivo by certain antibodies
results in remarkably robust alloantigen-specific immuno-
suppression and induction of specific transplantation toler-
ance, which is apparently mediated by regulatory T cells
secreting suppressive cytokines (31, 32). Finally, CD4 sig-
naling may also modify LFA-1–dependent adhesivity (33).
Little is known about the molecular mechanisms underly-
ing these inhibitory functions of CD4. However, CD4
cross-linking alone can induce signaling pathways similar to
those triggered by TCR (activation of Lck and Fyn, initia-
tion of the Ras-Raf-MAPK, and phospholipase C -PKC-
Ca2  pathways, resulting in activation of the NF AT,
NF B, and AP-1 transcription factors) (34, 35). The final
result of signaling mediated solely via CD4 may be either
induction of apoptosis or presensitization of T cells to
CD3-mediated apoptosis (34, 36, 37).
It is tempting to speculate that LIME is involved in these
inhibitory aspects of CD4 signaling: it may, for example,
compete with CD4 for Lck and at the same time it may
bring more Csk to membrane rafts (Fig. 7 C). This could
eventually result in inhibition of Src family kinases, which
are needed for TCR signaling. This model of LIME func-
tion is, however, not very well compatible with our obser-
vation that Lck isolated from J77-LIME transfectants and
LIME-associated Lck (which is more phosphorylated on
the COOH-terminal inhibitory tyrosine) has a kinase ac-
tivity comparable to Lck from control cells. Nevertheless, it
is possible to propose the following model for LIME func-
tion (Fig. 9): cross-linking of CD4 induces aggregation or
reorganization of lipid rafts containing LIME, CD4-Lck,
and free Lck. By this, Lck (free or CD4-associated) is
brought into proximity of LIME and phosphorylates the
adaptor. Now, cytoplasmic Csk and free Lck bind to tyro-
sine-phosphorylated LIME via their SH2 domains. In the
resulting complex, Csk phosphorylates Lck on Y505 (either
on the same LIME adaptor or on a different LIME mole-
cule in close proximity). However, the Lck phosphorylated
on Y505 remains enzymatically active because its SH2 do-
main is bound to phospho-LIME and thus cannot be
engaged by phospho-Y505 (with the consequence that
the inactivating “closed” conformation of Lck cannot be
formed). LIME-associated, “open” Lck could phosphory-
late additional molecules thus propagating the CD4-medi-
ated signal. In addition (or alternatively), phospho-Y505 of
LIME-bound Lck could serve as a docking site for addi-
tional signaling proteins (including Lck or Fyn). Recruit-
ment of these molecules to the LIME–Csk–Lck complex
could further amplify the CD4-mediated signal. Subse-
quently, the phosphorylated Lck may dissociate from
LIME, assume the “closed” conformation, and remain in-
active in the lipid raft. A model in which LIME-associated
Lck recruits and activates lipid raft-associated Fyn might
explain the recent report that the activation of Fyn within
the lipid microdomains is preceded (and requires) translo-
cation of Lck to lipid rafts (38).
A remarkable feature of LIME is its downmodulation in
T cells after stimulation with PHA or immobilized anti-
CD3 antibodies and its reappearance after removal of the
stimulating agents. A plausible explanation could be that
down-regulation of LIME serves to limit CD3/TCR-
Figure 9. Hypothetical mechanism of LIME involvement in regulation
of Lck activity.T
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mediated activation processes by blunting coreceptor sig-
naling. Such a mechanism could help to prevent hyperacti-
vation of T cells that have already seen antigen and start to
differentiate into effector T-lymphocytes.
In summary, we suggest that the newly described lipid
raft-associated transmembrane adaptor protein LIME may
have regulatory function(s) in T cells. At the beginning of
an immune response where coreceptor signaling is required
to activate T cells, LIME rapidly becomes tyrosine-phos-
phorylated, transiently increases the activity of Lck by
blocking formation of its inactive conformation, and thus
amplifies TCR-mediated signals. Upon prolonged stimula-
tion, LIME helps to accumulate inhibited Lck in lipid rafts,
thereby preventing hyperactivation of T cells. In the case of
antigen persistence, T cells down-regulate expression of
LIME. This may be a mechanism to prevent premature ter-
mination of the immune response by blunting membrane
recruitment of enzymatically active Lck. Furthermore, one
may speculate that strongly positive nonphosphorylated
LIME may possibly interact with membrane phospholipids
or other negatively charged cytoplasmic molecules (e.g.,
phosphoproteins) and thereby modify their interactions
with other signaling molecules. To fully understand the role
of LIME during T cell activation, it will be necessary to ex-
plore its possible functional interactions with PAG/Cbp,
another raft-associated transmembrane adaptor that regulates
the activity of Src kinases by recruiting Csk (10, 11). More-
over, more definitive answers regarding the physiological
role of LIME in T cell activation should be provided by
LIME knock-out mice, currently under construction.
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